MA50223A - Sels inhibiteurs de ferroportine - Google Patents

Sels inhibiteurs de ferroportine

Info

Publication number
MA50223A
MA50223A MA050223A MA50223A MA50223A MA 50223 A MA50223 A MA 50223A MA 050223 A MA050223 A MA 050223A MA 50223 A MA50223 A MA 50223A MA 50223 A MA50223 A MA 50223A
Authority
MA
Morocco
Prior art keywords
ferroportine
inhibitor salts
inhibitor
salts
ferroportine inhibitor
Prior art date
Application number
MA050223A
Other languages
English (en)
Inventor
Fritz Blatter
Michael Burgert
Giuseppe Lapadula
Collin D Morris
Erik Philipp
Stefan Reim
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of MA50223A publication Critical patent/MA50223A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050223A 2017-04-18 2018-04-18 Sels inhibiteurs de ferroportine MA50223A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17166907 2017-04-18

Publications (1)

Publication Number Publication Date
MA50223A true MA50223A (fr) 2020-07-22

Family

ID=58549089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050223A MA50223A (fr) 2017-04-18 2018-04-18 Sels inhibiteurs de ferroportine

Country Status (13)

Country Link
US (1) US11129820B2 (fr)
EP (1) EP3612528B1 (fr)
JP (1) JP7065115B2 (fr)
CN (1) CN110785417B (fr)
AU (1) AU2018253864B2 (fr)
BR (1) BR112019021800A2 (fr)
EA (1) EA201992144A1 (fr)
ES (1) ES3055044T3 (fr)
IL (1) IL269812A (fr)
JO (1) JOP20180036A1 (fr)
MA (1) MA50223A (fr)
TN (1) TN2019000281A1 (fr)
WO (1) WO2018192973A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
MX2022000782A (es) * 2019-07-19 2022-04-18 Vifor Int Ag Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
EP3999060A1 (fr) 2019-07-19 2022-05-25 Vifor (International) Ag Inhibiteurs de ferroportine destinés à être utilisés dans la prévention et le traitement de lésions rénales
WO2021018023A1 (fr) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
AU2020369137A1 (en) 2019-10-22 2022-04-07 Vifor (International) Ag Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (VIT-2763)
KR20220125326A (ko) * 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
CN115362154A (zh) * 2020-03-24 2022-11-18 威佛（国际）股份公司 膜铁转运蛋白抑制剂的制备方法
CA3181583A1 (fr) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methodes d'utilisation de pyrimidines en tant qu'inhibiteurs de la ferroportine
US12559502B2 (en) 2020-04-28 2026-02-24 Global Blood Therapeutics, Inc Thieno pyrimidines as ferroportin inhibitors
WO2021222363A1 (fr) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Pyrimidines cycloalkyliques utilisées en tant qu'inhibiteurs de la ferroportine
KR20230134476A (ko) * 2021-01-20 2023-09-21 비포르 (인터내셔날) 아게 골수이형성 증후군(mds)의 치료에 사용하기 위한 페로포틴-억제제
KR20230169981A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 적혈구증가증을 치료하기 위한 조성물 및 방법
TW202304896A (zh) * 2021-04-22 2023-02-01 瑞士商威佛（國際）股份有限公司 經修飾的膜鐵運輸蛋白(ferroportin)抑制劑
WO2023046664A1 (fr) 2021-09-21 2023-03-30 Vifor (International) Ag Inhibiteurs de ferroportine n-substitués
JP2025535398A (ja) 2022-10-21 2025-10-24 ビフォー （インターナショナル） エージー 二環式フェロポーチン阻害剤
EP4687983A1 (fr) 2023-03-27 2026-02-11 Silence Therapeutics GmbH Composés et compositions destinés à être utilisés dans une transplantation de cellules souches
CN116173218B (zh) * 2023-04-28 2023-08-04 北京大学口腔医学院 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途
AU2024310149A1 (en) 2023-06-26 2025-11-20 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025096992A1 (fr) * 2023-11-01 2025-05-08 Navinta, Llc Procédé d'isolement de dérisomaltose ferrique solide
WO2026041650A1 (fr) 2024-08-20 2026-02-26 Vifor (International) Ag Inhibiteurs de ferroportine destinés à être utilisés dans le traitement de la néphrite lupique

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937878A (en) 1959-12-24 1963-09-25 Ciba Ltd N-[5-nitro-(2)-furfurylidene]-pyrazole-carboxylic acid hydrazides and process for their manufacture
MY129541A (en) 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
AR009655A1 (es) 1996-12-10 2000-04-26 Novartis Ag Una composicion parenteralmente inyectable, un metodo para su preparacion, metodos para el tratamiento de enfermedades, una modificacion decristal de 1-decansulfonato de desferrioxamina, su uso, un proceso para la produccion de dicha modificacion de cristal y una preparacion farmaceutica que
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
CA2368026A1 (fr) 1999-03-22 2000-09-28 Bi-Huang Hu Banques combinatoires d'oxazole et de thiazole
EP1072265A1 (fr) 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Utilisation de polyphenols des plantes pour le traitement de la surcharge en fer
EP1074254A3 (fr) 1999-07-20 2002-09-11 MEDIS S.r.l. Medical Infusion Systems Utilisation de polyphenols végétaux avec des vitamines pour le traitement de la surcharge en fer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
AU2002356525A1 (en) 2001-09-24 2003-04-07 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
US20030109548A1 (en) 2001-11-09 2003-06-12 Royt Paulette W. Compositions and methods of treating iron excess
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
ES2375132T3 (es) 2003-07-21 2012-02-27 Merck Serono Sa Dicarboxamidas de arilo.
WO2005014576A1 (fr) 2003-08-12 2005-02-17 Takeda Pharmaceutical Company Limited Derive d'isoquinoline, procede permettant de produire ce derive, et utilisation de ce derive
DE10356409B4 (de) 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate
FR2870271B1 (fr) 2004-05-11 2008-03-14 Bruno Merand Procede de construction d'une maison en bois et moyens pour la mise en oeuvre du procede.
WO2006040646A1 (fr) 2004-10-14 2006-04-20 Pfizer, Inc. Amides de benzimidazole ou d'indole en tant qu'inhibiteurs de pin1
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
CA2605603A1 (fr) 2005-04-22 2006-11-02 Kalypsys, Inc. Inhibiteurs ortho-terphenyle de kinase p38 et procedes de traitement des troubles inflammatoires
WO2006127550A1 (fr) 2005-05-23 2006-11-30 Merck & Co., Inc. Antagonistes des recepteurs d'orexine a base de bis-amide de proline
AU2006255944B2 (en) 2005-06-08 2010-03-04 Japan Tobacco Inc. Heterocyclic compound
EP1928865A1 (fr) 2005-08-17 2008-06-11 Schering Corporation Ligands de kinase thiophene et furane a haute affinite
CA2630665C (fr) 2005-11-21 2011-03-15 Shionogi & Co., Ltd. Compose heterocyclique presentant une activite inhibitrice de la 11-.beta.-hydroxysteroide deshydrogenase de type i
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
EP1976835A2 (fr) 2006-01-13 2008-10-08 Takeda San Diego, Inc. Inhibiteurs des histone desacetylases
CN101611007A (zh) 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
CL2008000666A1 (es) 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
AR065785A1 (es) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro
EP2128171A1 (fr) 2007-03-20 2009-12-02 Meiji Seika Kaisha Ltd. Agent pour la prévention ou le traitement d'une surcharge de fer
CL2008000793A1 (es) 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
US8012972B2 (en) 2007-03-28 2011-09-06 Santen Pharmaceutical Co., Ltd. Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure
EP2068855A2 (fr) 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
CA2771226A1 (fr) 2008-08-22 2010-02-25 James Madden Nouveaux antagonistes du recepteur de la bradykinine b1
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
JP2012509275A (ja) 2008-11-19 2012-04-19 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害薬
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
EP2776411B1 (fr) 2011-11-07 2019-06-26 The University of Queensland Modulateurs des récepteurs c3a
HK1199892A1 (en) 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
EP2620142A1 (fr) 2012-01-27 2013-07-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Chemin de signalisation Hedgehog impliqué dans le métabolisme énergétique
AU2013235491A1 (en) 2012-03-22 2014-09-11 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
AR091022A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
CN103508957B (zh) 2012-06-25 2017-02-08 中国科学院上海药物研究所 羟乙基吡唑类化合物或氨乙基吡唑类化合物及其制备方法和用途
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
WO2015051362A1 (fr) 2013-10-04 2015-04-09 Illinois Institute Of Technology Chélateurs multifonctionnels, complexes, et compositions de ceux-ci, et leurs procédés d'utilisation
US20160243201A1 (en) 2013-11-05 2016-08-25 New York Blood Center, Inc. Methods and compositions for increasing hepcidin expession using modified iron binding/releasing transferrin
JP6838966B2 (ja) 2013-11-22 2021-03-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシン類似体およびその使用
AU2016342310B2 (en) 2015-10-23 2020-08-27 Vifor (International) Ag Novel ferroportin inhibitors

Also Published As

Publication number Publication date
CA3059533A1 (fr) 2018-10-25
CN110785417A (zh) 2020-02-11
JP2020516620A (ja) 2020-06-11
WO2018192973A1 (fr) 2018-10-25
AU2018253864B2 (en) 2021-08-19
EP3612528B1 (fr) 2025-11-19
EP3612528C0 (fr) 2025-11-19
IL269812A (en) 2019-11-28
AU2018253864A1 (en) 2019-10-03
US11129820B2 (en) 2021-09-28
ES3055044T3 (en) 2026-02-09
TN2019000281A1 (en) 2021-05-07
CN110785417B (zh) 2023-05-23
BR112019021800A2 (pt) 2020-05-05
EA201992144A1 (ru) 2020-03-17
EP3612528A1 (fr) 2020-02-26
US20200113885A1 (en) 2020-04-16
JP7065115B2 (ja) 2022-05-11
JOP20180036A1 (ar) 2019-01-30

Similar Documents

Publication Publication Date Title
MA50223A (fr) Sels inhibiteurs de ferroportine
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
IL269196A (en) Novel inhibitors
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
MA42606A (fr) Sels d'un inhibiteur de lsd1
EP3626699A4 (fr) Inhibiteur de ssao
MA52812A (fr) Inhibiteurs de sarm1
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
MA47573A (fr) Inhibiteurs de dihydrobenzofurane glycosidase substitués
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
MA52813A (fr) Inhibiteurs de sarm1
DK3668955T3 (da) Korrosionsinhibitor
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3706747A4 (fr) Inhibiteurs de prmt5
EP3801499A4 (fr) Inhibiteurs de sarm1
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3383883A4 (fr) Sels de conjugués en cancéro-thérapie
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46889A (fr) Inhibiteurs de gsk-3
EP3706742A4 (fr) Inhibiteurs de prmt5
EP3600301A4 (fr) Inhibiteurs de kdm4
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase